Cowen reiterated their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report released on Wednesday.

Other equities analysts have also recently issued reports about the company. Zacks Investment Research raised Albireo Pharma from a hold rating to a buy rating and set a $36.00 price target on the stock in a report on Tuesday, July 24th. BidaskClub cut Albireo Pharma from a sell rating to a strong sell rating in a report on Saturday, July 28th. Wedbush reissued an outperform rating and set a $69.00 price target on shares of Albireo Pharma in a report on Tuesday, August 7th. Finally, Needham & Company LLC reissued a buy rating and set a $50.00 price target on shares of Albireo Pharma in a report on Tuesday. Two research analysts have rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $59.40.

ALBO stock traded up $0.62 during midday trading on Wednesday, hitting $25.62. The company’s stock had a trading volume of 3,332 shares, compared to its average volume of 66,026. The stock has a market capitalization of $291.71 million, a PE ratio of -8.15 and a beta of 1.74. Albireo Pharma has a 12 month low of $21.25 and a 12 month high of $39.87.

Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.20). The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $1.55 million. As a group, analysts predict that Albireo Pharma will post -3.39 EPS for the current year.

A number of institutional investors have recently made changes to their positions in ALBO. Northern Trust Corp raised its holdings in Albireo Pharma by 60.3% in the 1st quarter. Northern Trust Corp now owns 15,766 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 5,932 shares during the period. BlackRock Inc. raised its holdings in Albireo Pharma by 522.4% in the 1st quarter. BlackRock Inc. now owns 76,780 shares of the biopharmaceutical company’s stock worth $2,501,000 after purchasing an additional 64,444 shares during the period. Millennium Management LLC raised its holdings in Albireo Pharma by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after purchasing an additional 109,017 shares during the period. Chicago Capital LLC raised its holdings in Albireo Pharma by 48.4% in the 2nd quarter. Chicago Capital LLC now owns 134,748 shares of the biopharmaceutical company’s stock worth $4,784,000 after purchasing an additional 43,917 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Albireo Pharma in the 2nd quarter worth $165,000. 63.70% of the stock is currently owned by institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: Cost of Capital Explained

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.